STOCK GOODIES PLAYS OF THE WEEK

[PharmaGreen007]

InMed Pharmaceuticals-IMLFF

Why invest in InMed?

Looking at the latest presentation the Company has for February, you will notice that they have 3 programs in the pre-clinical stage as follows:
1) Ocular Diseases;
2) Joint Pain and Inflammation; and
3) Dermatology
Just to put the above in perspective, Glaucoma market under the ocular diseases has a market that would justify alone multiples to InMed’s current valuation.
What makes InMed a primary holding for us is the number of clinical trials that they could soon start initiating. In my 10 years of following stories with clinical trails, the most common matters we face are mitigated and those are:
1) Length of trail – typical clinical trial path takes 10 to 15 years for a drug to be approved. This is clearly draining to investors as its time consuming with very little valuation milestones unless the trial is a success at each of the phases. InMed’s Intelligent Cannabinoid Drug Design Platform or IDP shortens this path by one third of the time.
2) Cost of trail – clearly with a shorter time span for valuation milestones, the cost associated with these trials goes dramatically down. This is further reduced by Company’s ability to use a similar platform to that of GW, which we can elaborate more about in the near future.
3) Risk of attrition – in other words the risk of blow-ups. Those of you that understand clinical trials should realize that using a natural (non-synthetic) cannabinoid clearly reduces the risk of failed trails. Clinical trails are risky by nature, but using non-synthetics reduces that risk. What makes this even less of a risk in InMed’s case is following the path of a successful model that GW has implemented. Again, soon I will be able to elaborate more as to why InMed has what is considered the secret sauce that worked for GW. Clearly until trails start and success is achieved we can only use public data to make an informed speculative recommendation.

So the combination of having many programs that are expected to soon start pre-clinical or even clinical trails, lower attrition risk, shorter path for approval and lower cost of such programs make us get behind InMed. I initiated coverage sub 15 and said buying anything sub 20 cents is pretty safe. Clearly as soon as the placement is officially closed and some more milestones are announced, we will likely suggest that entering at a higher level will continue to be safe. For now sub 25 cents on the momentum that was built last week seems like a very reasonable entry.

MMN
https://twitter.com/makingmoneynow1

Read more at http://www.stockhouse.com/companies/bullboard/c.in/inmed-pharmaceuticals-inc#xGKsr5CPVPDigpqA.99

http://www.inmedpharma.com/s/home.asp